[Clinical, cytological and immunological characteristics of the effect of ENKAD on the mouth mucosa in Sjögren's syndrome].
A study of the clinical efficacy and the immunomodulating and antiinflammatory effect of ENCAD was conducted in 20 patients with Sjogren's disease (SD) of various degrees of activity of oral mucosa involvement and in a group of 23 healthy controls, with a saline solution as placebo. ENCAD was shown to lessen the expression of the clinical symptoms of xerostomia in both groups of a low and a moderate and high degrees of local activity of an inflammatory process. A tendency to the normalization of regeneration and desquamation in the oral mucosa epithelium was observed against a background of the reduction of an inflammatory reaction. ENCAD produced an immuno modulating effect lowering the blood level of theophylline-resistant and raising the level of theophylline-sensitive T-lymphocytes.